The company, founded by the creator of RX Bar, has a compelling investment narrative due to explosive initial sales, a strategic acquisition of its key ingredient supplier (Epigee), and a strong product-market fit in the 'protein boom'. It is a company to watch for a potential IPO. A notable risk is that its product is considered an ultra-processed food.